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Abstract
OBJECTIVE: Few studies have investigated the ef-
fects produced by combinations of polysaccharides
and chemotherapeutic drugs in cancer treatment.
We hypothesized that a combination of polysaccha-
rides (COP) from Lentinus edodes and Tricholoma
matsutake would improve the efficacy of 5-fluoro-
uracil (5-FU)-mediated inhibition of H22 cell
growth.
METHODS: Mice were injected H22 cells and then
treated with either 5-FU, polysaccharides from Tri-
choloma matsutake (PTM), polysaccharides from
Lentinus edodes (PL), PTM+PL, 5-FU+PTM, 5-FU+
PL, or 5-FU + COP. The tumor weight and volume,
and splenic CD4 + and CD8 + T cell frequencies,
were determined. Additionally, splenic natural killer
(NK) cell and cytotoxic T lymphocyte (CTL) activities
were assessed and the serum levels of tumor necro-
sis factor-α (TNF-α), Interleukin-2 (IL-2), and Interfer-
on-γ (IFN-γ) were measured.
RESULTS: Compared with mice from the control,
5-FU, PL, PTM, PTM+PL, 5-FU+PL, and 5-FU+PTM
groups, mice treated with 5-FU + COP showed: (a)
significantly reduced tumor weight and volume (P<
0.05); (b) significantly higher serum levels of TNF-α,
IL-2, and IFN-γ (P<0.05); (c) significantly increased
CD4+ and CD8+ T cell frequencies in the spleen (P<
0.05); and (d) significantly increased splenic NK cell
and CTL activities (P<0.05). The tumor weight and
volume in mice treated with 5-FU+PL or 5-FU+PTM
were significantly reduced compared with mice
treated with 5-FU alone (P<0.05). Serum levels of
TNF-α, IL-2, and IFN-γ, frequencies of CD4 + and
CD8+ T cells in the spleen, and splenic NK and CTL
activities were also significantly increased in mice
treated with 5-FU+PL or 5-FU+PTM compared with
mice treated with 5-FU alone (P<0.05).
CONCLUSION: Polysaccharides from Lentinus
edodes and Tricholoma matsutake could enhance
the efficacy of 5-FU-mediated H22 cell growth inhi-
bition.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Cancer is the one of the leading causes of death among
adults in China.1 In clinical practice, cancer is treated
by surgically removing the tumor and then administer-
ing chemotherapy.2 The disadvantages of chemothera-
py are its lack of specificity and the destruction of lym-
phocytes, cells that play a pivotal role in combating tu-
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mors.3 Moreover, immunosuppression has been detect-
ed in patients with cancers.4,5 Therefore, developing
therapies to improve immune responses in cancer pa-
tients is critical for advancing cancer treatment. Many
studies have reported that polysaccharides have immu-
nomodulatory or antitumor activities, and that polysac-
charides from different herbs have different activi-
ties.6-11 Byeon et al 12 observed that polysaccharides
from Tricholoma matsutake (PTM) could activate
splenic lymphocytes,13 while Harada et al 14 found that
polysaccharides from Lentinus edodes (PL) had antitu-
mor bioactivities. Thus, we hypothesized that a combi-
nation of polysaccharides (COP) that included PTM
and PL might show better efficacy in inhibiting tumor
cell growth. However, few studies have explored the ef-
fects induced by chemotherapeutic drugs with combi-
nations of polysaccharides from different herbs on tu-
mor cell growth. Hepatocellular carcinoma (HCC) is
the third most frequent cause of cancer-related death
worldwide, and most patients with HCC die within
1 year of diagnosis.15,16 5-fluorouracil (5-FU) is a che-
motherapeutic drug that is frequently used in HCC
treatment. The aim of the study was to investigate
whether COP might enhance the efficacy of 5-FU in
the growth inhibition of H22 cells, a mouse hepato-
ma line.
MATERIALS ANDMETHODS
Reagents
PL and PTM were provided by Bangbao Biotech., Co.,
Ltd. (Zhejiang, China). Polysaccharides were dissolved
in phosphate-buffered saline (PBS). The 5-FU (25 mg/
mL) was from Tianjin Jinyao Amino Acids Co., Ltd.
(Tianjin, China).
Cell culture
P815 mastocytoma cells, YAC-1 cells, and H22 cells
were cultured in RPMI-1640 (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(FBS) (Invitrogen, Carlsbad, CA, USA) in an atmo-
sphere of 5% CO2 at 37℃ . Cells in the logarithmic
growth phase were used for experiments.
Effects of PL on tumor cell growth
H22 cells (a generous gift from the central lab of Chi-
na-Japan Union Hospital of Jilin University, Jilin, Chi-
na) in the logarithmic growth phase were plated in
96-well plates (Corning Incorporated, Corning, NY,
USA) at 1×104 cells/well. When the confluence of cells
was 80%-90%, PL was added to the cells in triplicate
at different doses, i.e. 0, 50, 100, 200, 300, 400, or
500 μg/mL. Cells were incubated with PL for 12, 24,
36, 48, 60, or 72 h, respectively. At 4 h before the end
of the incubation period, 20 μL 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma-Aldrich, St. Louis, MO, USA) at a concentra-
tion of 5 mg/mL was added to each well. After 4 h, un-
reacted dye was removed by aspiration and the blue
MTT formazan precipitate was dissolved by adding
150 μL Dimethyl sulfoxide (DMSO) (Sigma-Aldrich,
St. Louis,MO,USA) to eachwell. Absorbance at 490 nm
was measured and results were expressed as percentages
of the control.
The effects of PTM on lymphocyte growth
In a sterilized hood, spleens were removed from
8-week-old SPF-grade male C57BL/6 mice that
weighed 18-22 g [Laboratory Animal Center of Jilin
University, Jilin, China; Certificate of Quality No.
SCXK (ji)2008-0005]. After spleens were mashed, sus-
pended in PBS (Beyotime Biotechnology Co., Ltd., Ji-
angsu, China), and filtered through 200 mesh sieves
(Beijing Solarbio Technology Co., Ltd., Beijing, Chi-
na), ammonium chloride was added to lyse erythro-
cytes. After lysis, splenocytes were washed with PBS
three times. The cell concentration was adjusted to 5×
106/mL with RPMI-1640 (Invitrogen, Carlsbad, CA,
USA), and 5×105 cells per well were plated in 96-well
plates (Corning Incorporated, Corning, NY, USA).
PTM was added to the cells in triplicate at different
doses, i.e., 0, 50, 100, 200, 300, 400, or 500 μg/mL.
ConA (Sigma–Aldrich, St. Louis, MO, USA) was add-
ed to the cells at a final concentration of 5 μg/mL or
RPMI-1640 alone was added as a control. Cells were
incubated in an atmosphere of 5% CO2 at 37℃ for 12,
24, 36, 48, 60, or 72 h. The MTT assay to detect cell
viability was conducted as described above. The Stimu-
lation Index (SI) was calculated by the formula:
Animal experiments
All protocols and procedures for animal experiments
were approved by the Jilin University Institutional Ani-
mal Care and Use Committee. Male and female
8-week-old SPF-grade ICR (Institute of Cancer Re-
search) mice that weighed 18-22 g were purchased
from the Laboratory Animal Center of Jilin University,
China [Certificate of Quality No. SCXK (ji)
2008-0005]. Prior to experiments, 80 mice were al-
lowed to adapt to the environment for 1 week. Using a
random number table method, mice were assigned to
one of eight experimental groups: control, 5-FU (30 mg/
kg), PL, PTM, PL+PTM (COP), 5-FU+PL, 5-FU+
PTM, or 5-FU+COP. Each group contained 10 mice
that were treated as follows:
Control, 1.5×105 H22 cells in 0.2 mL PBS were inject-
ed subcutaneously in the right thigh.
5-FU, 1.5×105 H22 cells in 0.2 mL PBS were injected
subcutaneously in the right thigh; 24 h later, 5-FU was
injected intraperitoneally following 10-day cycles with
mice receiving injections on days 1-5.
PL, 1.5 × 105 H22 cells in 0.2 mL PBS were injected
subcutaneously in the right thigh; 24 h later, 1200 mg/
OD (cells stimulated by ConA)
OD (cells without ConA)SI=
kg body weight PL was injected gastrically daily.
PTM, 1.5×105 H22 cells in 0.2 mL PBS were injected
subcutaneously in the right thigh; 24 h later, 1200 mg/
kg body weight PTM was injected gastrically daily.
COP, 1.5×105 H22 cells in 0.2 mL PBS were injected
subcutaneously in the right thigh; 24 h later, 1200 mg/
kg body weight PL+PTM (1∶1) was injected gastrically
daily.
5-FU+PL, 1.5×105 H22 cells in 0.2 mL PBS were in-
jected subcutaneously in the right thigh; 24 h later,
1200 mg/kg body weight PL was injected gastrically
daily, and 5-FU was injected intraperitoneally follow-
ing 10-day cycles with mice receiving injections on
days 1-5.
5-FU+PTM, 1.5×105 H22 cells in 0.2 mL PBS were in-
jected subcutaneously in the right thigh; 24 h later,
1200 mg/kg body weight PTM was injected gastrically
daily, and 5-FU was injected intraperitoneally follow-
ing 10-day cycles with mice receiving injections on
days 1-5.
5-FU+COP, 1.5×105 H22 cells in 0.2 mL PBS were in-
jected subcutaneously in the right thigh; 24 h later,
1200 mg/kg body weight PL+PTM (1∶1) was injected
gastrically daily, and 5-FU was injected intraperitoneal-
ly following 10-day cycles with mice receiving injec-
tions on days 1-5.
Tumor weight and volume
When all mice in the control group developed palpable
tumors, mice from all groups were anesthetized and
killed, and all tumors were removed and weighed. The
volume of each tumor was calculated by the formula:
tumor volume=1/2ab2, where 'a' is the largest diameter
and 'b' is the perpendicular diameter.17
Assay for CTL activity
C57BL/6 mice were killed and spleens were removed
in a sterilized hood. After spleens were mashed, sus-
pended in PBS, and filtered through 200-micron mesh
sieves, ammonium chloride was added to lyse erythro-
cytes. After lysis, splenocytes were washed with PBS
three times. Splenocytes were used as effector cells and
P815 mastocytoma cells (a generous gift from the cen-
tral lab of China-Japan Union Hospital of Jilin Univer-
sity, Jilin, China) were used as target cells at a ratio of
effector cells to target cells of 20∶1 and incubated for
24 h. After incubation, supernatants were collected
and CTL activity was measured using the lactate dehy-
drogenase (LDH) release assay according to the manu-
facturer's instructions (Nanjing Jiancheng Bioengineer-
ing Corp., Nanjing, China). The percentage of cytotox-
icity was calculated as follows: (E-C)/(M-C) × 100,
where C is the background release in medium alone,
M is the maximal lysis obtained with Triton X-100
(Sigma–Aldrich, St. Louis, MO, USA), and E is the
value measured for the experimental supernatant.
Assays for natural killer cell activity
YAC-1 cells (a generous gift from the central lab of
China-Japan Union Hospital of Jilin University, Jilin,
China) were used as target cells and splenocytes were
used as effector cells at a ratio of effector cells to target
cells of 20∶1. Cells were incubated for 24 h. After incu-
bation, supernatants were collected and natural killer
(NK) cell activities were determined using the LDH re-
lease assay according to the manufacturer's instructions
(Nanjing Jiancheng Bioengineering Corp., Nanjing,
China). The percentage of cytotoxicity was calculated
as follows: (E-C)/(M-C) ×100, where C was the back-
ground release in medium alone, M was the maximal
lysis obtained with Triton X-100, and E was the value
measured for the experimental supernatant.
CD4+ and CD8+ T cell quantification in the spleen
Mice were anesthetized and killed and spleens were re-
moved from mice of different groups in a sterilized
hood. After spleens were mashed, suspended in PBS,
and filtered through 200-micron mesh sieves, ammoni-
um chloride was added to lyse erythrocytes. After lysis,
splenocytes were washed with PBS three times. Cells
were counted and 1×106 cells in 200 μL PBS were ali-
quoted into 1.5-mLmicrotubes.To each aliquot, 2.5 μL
PE anti-mouse CD8 (BioLegend, San Diego, CA,
USA) and 1 μL FITC anti-mouse CD4 (BioLegend)
were added. Cells were incubated at 4℃ in the dark for
30 min. After incubation, cells were washed with PBS
and the supernatant was discarded. Then, 500 μL PBS
was added and CD4+ and CD8+ T cells were quanti-
fied by flow cytometry (Becton Dickinson, Franklin
Lakes, NJ, USA).
Measurements of tumor necrosis factor-α (TNF-α), In-
terleukin-2 (IL-2), and Interferon-γ (IFN-γ) levels in
the serum
After mice were anesthetized, blood was collected and
serum was prepared. Serum levels of TNF-α, IL-2, and
IFN-γ were measured by Enzyme linked immunosor-
bent assay (ELISA) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA).
Statistical analyses
The SPSS 13.0 (SPSS Inc., Chicago, IL, USA) soft-
ware package was used for statistical analyses. All re-
sults were expressed as the mean ± standard deviation
(SD). One-factor analysis of variance (ANOVA) was
used for comparisons among groups and the least sig-
nificant difference (LSD) test was used for compari-
sons between groups. Statistically significant differenc-
es were defined as P<0.05.
RESULTS
Effects of PL on the growth of H22 cells
The results of the MTT assay indicated that the viabili-
ty of H22 cells incubated with PL decreased with time
(Figure 1). Inhibition of H22 cell growth was seen at
all PL concentrations ranging from 50 to 500 μg/mL,
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kg body weight PL was injected gastrically daily.
PTM, 1.5×105 H22 cells in 0.2 mL PBS were injected
subcutaneously in the right thigh; 24 h later, 1200 mg/
kg body weight PTM was injected gastrically daily.
COP, 1.5×105 H22 cells in 0.2 mL PBS were injected
subcutaneously in the right thigh; 24 h later, 1200 mg/
kg body weight PL+PTM (1∶1) was injected gastrically
daily.
5-FU+PL, 1.5×105 H22 cells in 0.2 mL PBS were in-
jected subcutaneously in the right thigh; 24 h later,
1200 mg/kg body weight PL was injected gastrically
daily, and 5-FU was injected intraperitoneally follow-
ing 10-day cycles with mice receiving injections on
days 1-5.
5-FU+PTM, 1.5×105 H22 cells in 0.2 mL PBS were in-
jected subcutaneously in the right thigh; 24 h later,
1200 mg/kg body weight PTM was injected gastrically
daily, and 5-FU was injected intraperitoneally follow-
ing 10-day cycles with mice receiving injections on
days 1-5.
5-FU+COP, 1.5×105 H22 cells in 0.2 mL PBS were in-
jected subcutaneously in the right thigh; 24 h later,
1200 mg/kg body weight PL+PTM (1∶1) was injected
gastrically daily, and 5-FU was injected intraperitoneal-
ly following 10-day cycles with mice receiving injec-
tions on days 1-5.
Tumor weight and volume
When all mice in the control group developed palpable
tumors, mice from all groups were anesthetized and
killed, and all tumors were removed and weighed. The
volume of each tumor was calculated by the formula:
tumor volume=1/2ab2, where 'a' is the largest diameter
and 'b' is the perpendicular diameter.17
Assay for CTL activity
C57BL/6 mice were killed and spleens were removed
in a sterilized hood. After spleens were mashed, sus-
pended in PBS, and filtered through 200-micron mesh
sieves, ammonium chloride was added to lyse erythro-
cytes. After lysis, splenocytes were washed with PBS
three times. Splenocytes were used as effector cells and
P815 mastocytoma cells (a generous gift from the cen-
tral lab of China-Japan Union Hospital of Jilin Univer-
sity, Jilin, China) were used as target cells at a ratio of
effector cells to target cells of 20∶1 and incubated for
24 h. After incubation, supernatants were collected
and CTL activity was measured using the lactate dehy-
drogenase (LDH) release assay according to the manu-
facturer's instructions (Nanjing Jiancheng Bioengineer-
ing Corp., Nanjing, China). The percentage of cytotox-
icity was calculated as follows: (E-C)/(M-C) × 100,
where C is the background release in medium alone,
M is the maximal lysis obtained with Triton X-100
(Sigma–Aldrich, St. Louis, MO, USA), and E is the
value measured for the experimental supernatant.
Assays for natural killer cell activity
YAC-1 cells (a generous gift from the central lab of
China-Japan Union Hospital of Jilin University, Jilin,
China) were used as target cells and splenocytes were
used as effector cells at a ratio of effector cells to target
cells of 20∶1. Cells were incubated for 24 h. After incu-
bation, supernatants were collected and natural killer
(NK) cell activities were determined using the LDH re-
lease assay according to the manufacturer's instructions
(Nanjing Jiancheng Bioengineering Corp., Nanjing,
China). The percentage of cytotoxicity was calculated
as follows: (E-C)/(M-C) ×100, where C was the back-
ground release in medium alone, M was the maximal
lysis obtained with Triton X-100, and E was the value
measured for the experimental supernatant.
CD4+ and CD8+ T cell quantification in the spleen
Mice were anesthetized and killed and spleens were re-
moved from mice of different groups in a sterilized
hood. After spleens were mashed, suspended in PBS,
and filtered through 200-micron mesh sieves, ammoni-
um chloride was added to lyse erythrocytes. After lysis,
splenocytes were washed with PBS three times. Cells
were counted and 1×106 cells in 200 μL PBS were ali-
quoted into 1.5-mLmicrotubes.To each aliquot, 2.5 μL
PE anti-mouse CD8 (BioLegend, San Diego, CA,
USA) and 1 μL FITC anti-mouse CD4 (BioLegend)
were added. Cells were incubated at 4℃ in the dark for
30 min. After incubation, cells were washed with PBS
and the supernatant was discarded. Then, 500 μL PBS
was added and CD4+ and CD8+ T cells were quanti-
fied by flow cytometry (Becton Dickinson, Franklin
Lakes, NJ, USA).
Measurements of tumor necrosis factor-α (TNF-α), In-
terleukin-2 (IL-2), and Interferon-γ (IFN-γ) levels in
the serum
After mice were anesthetized, blood was collected and
serum was prepared. Serum levels of TNF-α, IL-2, and
IFN-γ were measured by Enzyme linked immunosor-
bent assay (ELISA) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA).
Statistical analyses
The SPSS 13.0 (SPSS Inc., Chicago, IL, USA) soft-
ware package was used for statistical analyses. All re-
sults were expressed as the mean ± standard deviation
(SD). One-factor analysis of variance (ANOVA) was
used for comparisons among groups and the least sig-
nificant difference (LSD) test was used for compari-
sons between groups. Statistically significant differenc-
es were defined as P<0.05.
RESULTS
Effects of PL on the growth of H22 cells
The results of the MTT assay indicated that the viabili-
ty of H22 cells incubated with PL decreased with time
(Figure 1). Inhibition of H22 cell growth was seen at
all PL concentrations ranging from 50 to 500 μg/mL,
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and maximum inhibition occurred with 200 μg/mL
between 36 and 48 h. These results indicated that PL
could kill tumor cells.
Effects of PTM on lymphocytes in vitro
The SI of lymphocytes incubated with PTM increased
with time (Figure 2). Maximal stimulation was ob-
served at 200 μg/mL PTM.
Effects of 5-FU and COP on tumor volume and
weight
Tumor weight and volume in mice treated with
5-FU and COP were significantly reduced compared
with those in the control, PL, PTM, COP, 5-FU,
5-FU+PL, or 5-FU+PTM treatment groups (Figure
3; P<0.05). The tumor weight and volume in mice
treated with 5-FU+PL or 5-FU+PTM were signifi-
cantly reduced compared with those treated with
5-FU alone (P<0.05). The tumor weight and volume
in mice treated with 5-FU alone were significantly re-
duced compared with those treated with PL, PTM,
or COP (P<0.05).
Effects of 5-FU and COP on CTL and NK cell
activities in vivo
The CTL and NK cell activities in mice treated with
Figure 2 SI changes in lymphocytes incubated with PTM for indicated times
Lymphocytes were plated in triplicate and incubated with PTM. The SI of lymphocytes incubated with PTM increased with time.
Maximal stimulation was observed at 200 μg/mL PTM. SI: stimulation index; PTM: polysaccharides from tricholoma matsutake.
Figure 1 Changes in H22 cell viability after incubation with PL for the indicated times
H22 cells were incubated with PL in triplicate. Inhibition of H22 cell growth was seen at all PL concentrations ranging from 50 to
500 μg/mL, and maximum inhibition occurred with 200 μg/mL between 36 and 48 h. These results indicated that PL could kill tu-
mor cells. PL: polysaccharides from Lentinus edodes.
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5-FU + COP were significantly greater than in mice
treated with 5-FU, 5-FU+PL, or 5-FU+PTM (Figure 4;
P<0.05). Also, CTL and NK cell activities in mice
treated with COP were significantly greater than in
mice in the control, 5-FU, PL, PTM, 5-FU + PL,
5-FU+PTM, or 5-FU+COP treatment groups (Figure
4; P<0.05).
Effects of 5-FU and COP on CD4+ and CD8+ T cells
in spleen
Mice treated with 5-FU+COP had significantly greater
frequencies of CD4+ and CD8+ T cells in the spleen
compared with mice treated with 5-FU, 5-FU + PL,
or 5-FU+PTM (Figure 5; P<0.05). Also, mice treat-
ed with COP had significantly increased frequencies
of CD4+ and CD8+ T cells in the spleen compared
with mice treated with 5-FU, PL, PTM, 5-FU+PL,
5-FU + PTM, or 5-FU + COP (Figure 5; P<0.05),
which indicated that COP treatment promoted an in-
crease in the frequency of CD4+ and CD8+ T cells
in the spleen.
Effects of 5-FU and COP on serum cytokine levels
Serum levels of TNF-α, IL-2, and IFN-γ in mice treat-
ed with 5-FU+COP were significantly higher than in
mice treated with 5-FU, 5-FU + PL, or 5-FU + PTM
(Figure 6). Also, serum levels of TNF-α, IL-2, and
IFN-γ in mice treated with COP were significantly
higher than in mice treated with PL, PTM, 5-FU,
5-FU+PL, 5-FU+PTM, or 5-FU+COP, suggesting that
COP enhanced tumor cell killing by stimulating cyto-
kine secretion (Figure 6).
DISCUSSION
The major finding in our study was that COP could
3
Figure 3 Comparison of tumor weight and volume in mice from different groups
A: tumor weight; B: tumor volume. The indicated treatment groups received: control: PBS; 5-FU: 30 mg/kg 5-FU; PL: 1200 mg·kg-1·
d-1 PL; PTM: 1200 mg·kg-1·d-1 PTM; COP: 1200 mg·kg-1·d-1 COP; 5-FU+PL: 30 mg/kg 5-FU and 1200 mg·kg-1·d-1 PL; 5-FU+PTM:
30 mg/kg 5-FU and 1200 mg·kg-1·d-1PTM; and 5-FU+COP: 30 mg/kg 5-FU and 1200 mg·kg-1·d-1 COP. Mice were anesthetized and
killed and tumors were removed, weighed, and measured; n=10 per group. 5-FU: 5-fluorouracil; PL: polysaccharides from Lenti-
nus edodes; PTM: polysaccharides from Tricholoma matsutake; COP: combination of polysaccharides. aP<0.05, compared with the
control group; bP<0.05, compared with the 5-FU group; cP<0.05, compared with the 5-FU+COP group.
A B
28
Figure 4 Comparison of CTL and NK cell activities from different groups
A: CTL; B: NK. The indicated treatment groups received: control: PBS; 5-FU: 30 mg/kg 5-FU; PL: 1200 mg·kg-1·d-1 PL; PTM: 1200 mg·
kg-1·d-1 PTM; COP: 1200 mg·kg-1·d-1 COP; 5-FU+PL: 30 mg/kg 5-FU and 1200 mg·kg-1·d-1 PL; 5-FU+PTM: 30 mg/kg 5-FU and
1200 mg·kg-1·d-1 PTM; and 5-FU+COP: 30 mg/kg 5-FU and 1200 mg·kg-1·d-1 COP. Splenocytes from six mice per group were col-
lected and tested for CTL and NK cell activities. CTL: cytotoxic T lymphocyte; NK: natural killer; 5-FU: 5-fluorouracil; PL: polysaccha-
rides from Lentinus edodes; PTM: polysaccharides from Tricholoma matsutake; COP: combination of polysaccharides. aP<0.05,
compared with the control group; bP<0.05, compared with the 5-FU group; cP<0.05, compared with the 5-FU+COP group.
A B
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A B
Figure 5 Comparison of frequency of splenic CD4+ and CD8+ T cells in different treatment groups
A: CD4+; B: CD8+. The indicated treatment groups received: control: PBS; 5-FU: 30 mg/kg 5-FU; PL: 1200 mg·kg-1·d-1 PL;
PTM: 1200 mg·kg-1·d-1 PTM; COP: 1200 mg·kg-1·d-1 COP; 5-FU+PL: 30 mg/kg 5-FU and 1200 mg·kg-1·d-1 PL; 5-FU+PTM: 30 mg/kg
5-FU and 1200 mg·kg-1·d-1 PTM; and 5-FU+COP: 30 mg/kg 5-FU and 1200 mg·kg-1·d-1 COP. Splenocytes from six mice per group
were harvested and CD4+ and CD8+ T cells were quantified. 5-FU: 5-fluorouracil; PL: polysaccharides from Lentinus edodes; PTM:
polysaccharides from Tricholoma matsutake; COP: combination of polysaccharides. aP<0.05, compared with the control group; bP<
0.05, compared with the 5-FU group; cP<0.05, compared with the 5-FU+COP group.
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Figure 6 Comparison of serum TNF-α, IL-2, and IFN-γ levels in mice
in different treatment groups
A: TNF-α; B: IL-2; C: IFN-γ. The indicated treatment groups received:
control: PBS; 5-FU: 30 mg/kg 5-FU; PL: 1200 mg·kg-1·d-1 PL; PTM:
1200 mg·kg-1·d-1 PTM; COP: 1200 mg·kg-1·d-1 COP; 5-FU+PL: 30 mg/
kg 5-FU and 1200 mg·kg-1·d-1 PL; 5-FU+PTM: 30 mg/kg 5-FU and
1200 mg·kg-1·d-1PTM; and 5-FU+COP: 30 mg/kg 5-FU and 1200 mg·
kg-1·d-1 COP. Serum was collected from 10 mice per group. TNF-α: tu-
mor necrosis factor-α; IL-2: Interleukin-2; IFN-γ: Interferon-γ; 5-FU:
5-fluorouracil; PL: polysaccharides from Lentinus edodes; PTM: poly-
saccharides from Tricholoma matsutake; COP: combination of poly-
saccharides. aP<0.05, compared with the control group; bP<0.05,
compared with the 5-FU group; cP<0.05, compared with the 5-FU+
COP group.
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enhance the efficacy of 5-FU-mediated growth inhibi-
tion of H22 cells. Also, tumor weight and volume
were significantly reduced in mice treated with COP
and 5-FU compared with mice treated with 5-FU
alone.
One of the mechanisms by which the combination of
these polysaccharides increases the efficacy of 5-FU on
H22 cell growth inhibition may be that the polysaccha-
rides can increase the activities of NK cells and CTLs.
In vivo, splenocytes from mice treated with COP signif-
icantly increased NK cell and CTL activities. As sug-
gested by Ooi and Liu, polysaccharides might boost
the host defense system by activating many types of im-
mune cells that are vitally important for the mainte-
nance of immune homeostasis.18 Our study confirmed
that polysaccharides can strengthen host defense and
increase the activities of NK cells and CTLs. Neverthe-
less, the immune activation properties of COP are
probably not sufficient to justify its sole use to treat
hepatoma, because COP alone-treated mice had signifi-
cantly increased tumor weight and volume.
COP can also act to inhibit cancer cell growth by stim-
ulating the secretion of cytokines related to tumor cell
death. In our in vivo experiments, mice that received
PTM + PL had significantly higher levels of TNF-α,
IFN-γ, and IL-2. These results are consistent with the
findings of Cai et al,19 who reported that in vivo poly-
saccharide administration could stimulate the produc-
tion of cytokines, as indicated by increased levels of se-
rum TNF-α and IFN-γ.
COP likely also enhanced 5-FU-mediated H22 cell
growth inhibition by increasing the frequency of
CD4+ and CD8+ T cells in the spleen. Lymphocytes
are critical for inducing tumor cell death. In a study by
Zhao et al,20 the frequency of CD4+ and CD8+ T cells
was also increased by polysaccharides. Additionally,
polysaccharides can help maintain the relative weight
of the thymus and spleen, organs that supply the lym-
phocytes needed for the host to generate antitumor im-
mune responses. In our study, the relative index of the
spleen and thymus was significantly greater in mice
treated with COP than in mice treated with 5-FU
alone.
In conclusion, COP can be used to enhance H22 cell
growth inhibition when used in combination with
5-FU. This synergy suggests that these two polysaccha-
rides can act more effectively together than singly to
bolster the inhibitory effects of 5-FU on H22 cell
growth.
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enhance the efficacy of 5-FU-mediated growth inhibi-
tion of H22 cells. Also, tumor weight and volume
were significantly reduced in mice treated with COP
and 5-FU compared with mice treated with 5-FU
alone.
One of the mechanisms by which the combination of
these polysaccharides increases the efficacy of 5-FU on
H22 cell growth inhibition may be that the polysaccha-
rides can increase the activities of NK cells and CTLs.
In vivo, splenocytes from mice treated with COP signif-
icantly increased NK cell and CTL activities. As sug-
gested by Ooi and Liu, polysaccharides might boost
the host defense system by activating many types of im-
mune cells that are vitally important for the mainte-
nance of immune homeostasis.18 Our study confirmed
that polysaccharides can strengthen host defense and
increase the activities of NK cells and CTLs. Neverthe-
less, the immune activation properties of COP are
probably not sufficient to justify its sole use to treat
hepatoma, because COP alone-treated mice had signifi-
cantly increased tumor weight and volume.
COP can also act to inhibit cancer cell growth by stim-
ulating the secretion of cytokines related to tumor cell
death. In our in vivo experiments, mice that received
PTM + PL had significantly higher levels of TNF-α,
IFN-γ, and IL-2. These results are consistent with the
findings of Cai et al,19 who reported that in vivo poly-
saccharide administration could stimulate the produc-
tion of cytokines, as indicated by increased levels of se-
rum TNF-α and IFN-γ.
COP likely also enhanced 5-FU-mediated H22 cell
growth inhibition by increasing the frequency of
CD4+ and CD8+ T cells in the spleen. Lymphocytes
are critical for inducing tumor cell death. In a study by
Zhao et al,20 the frequency of CD4+ and CD8+ T cells
was also increased by polysaccharides. Additionally,
polysaccharides can help maintain the relative weight
of the thymus and spleen, organs that supply the lym-
phocytes needed for the host to generate antitumor im-
mune responses. In our study, the relative index of the
spleen and thymus was significantly greater in mice
treated with COP than in mice treated with 5-FU
alone.
In conclusion, COP can be used to enhance H22 cell
growth inhibition when used in combination with
5-FU. This synergy suggests that these two polysaccha-
rides can act more effectively together than singly to
bolster the inhibitory effects of 5-FU on H22 cell
growth.
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